Effect of activated charcoal on rifampicin absorption in man. 1996

O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
College of Health Sciences, Nnamdi Azikiwe University Nnewi Campus, Anambra State, Nigeria.

The effect of activated charcoal (AC) on rifampicin excretion was investigated in six healthy volunteers. On three occasions, at weekly intervals, each subject received a 600 mg rifampicin with 350 ml of water; b+c one and two weeks later, 600 mg of rifampicin plus 7.5 and 15 g AC, respectively, in 350 ml of water as a charcoal slurry. Urinary levels of rifampicin were measured form 1-36 hr after ingestion. Treatment with AC led to 1.2 per cent urinary recovery of rifampicin; decreased excretion rate; and a much lower plateau indicative of reduced absorption.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007917 Leprostatic Agents Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. Antileprotic Agents,Leprostatics,Agents, Antileprotic,Agents, Leprostatic
D008297 Male Males
D002606 Charcoal An amorphous form of carbon prepared from the incomplete combustion of animal or vegetable matter, e.g., wood. The activated form of charcoal is used in the treatment of poisoning. (Grant & Hackh's Chemical Dictionary, 5th ed) Activated Charcoal,Actidose,Actidose-Aqua,Adsorba,Carbomix,Charbon,CharcoAid,CharcoCaps,Charcodote,Formocarbine,Insta-Char,Kohle-Compretten,Kohle-Hevert,Kohle-Pulvis,Kohle-Tabletten Boxo-Pharm,Liqui-Char,Norit,Ultracarbon,Charcoal, Activated
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
January 1972, Clinical pharmacology and therapeutics,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
January 1983, European journal of clinical pharmacology,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
September 1976, Pediatrics,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
December 1977, Lancet (London, England),
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
July 2017, Clinical pharmacokinetics,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
January 1980, European journal of clinical pharmacology,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
January 2001, Bollettino chimico farmaceutico,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
January 2001, American journal of therapeutics,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
September 1991, Human & experimental toxicology,
O E Orisakwe, and C E Dioka, and A N Okpogba, and C N Orish, and S I Ofoefule
June 1985, British journal of clinical pharmacology,
Copied contents to your clipboard!